
| Condition | Example biologic targets |
|---|---|
| Moderate to severe plaque psoriasis | IL-17 (e.g. secukinumab), IL-23 (e.g. risankizumab), TNF-alpha |
| Psoriatic arthritis (joint pain with psoriasis) | IL-17, IL-23, TNF-alpha |
| Moderate to severe atopic dermatitis | IL-4/IL-13 (e.g. dupilumab) |
| Chronic spontaneous urticaria (long-term hives) | IgE (e.g. omalizumab) |
| Hidradenitis suppurativa | TNF-alpha (e.g. adalimumab), IL-17 |